Professional Statements and Societal Positions Guidelines
National Comprehensive Cancer Network - 2021
National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia (WM) and lymphoplasmacytic lymphoma (v.1.2022) indicate that, for individuals with previously treated WM, stem cell transplantation may be appropriate in selected cases with either: high-dose therapy with autologous stem cell rescue or allogeneic cell transplant (myeloablative or nonmyeloablative). The Network noted that allogeneic cell transplantation “should ideally be undertaken in the context of a clinical trial.” For potential autologous cell transplantation candidates, the guidelines also provide suggested treatment regimens considered non-stem-cell toxic.
Mayo Clinic Cancer Center - 2017
In 2017, the Mayo Clinic Cancer Center updated its guidelines on the diagnosis and management of WM. The guidelines noted that individuals who are potentially eligible for autologous hematopoietic cell transplantation (HCT; <70 years of age and with chemosensitive disease), should consider harvesting stem cells during first remission after a low tumor burden has been achieved. The guidelines recommended: “Autologous HCT should be considered for first or second relapse in transplant-eligible individuals with chemosensitive disease, especially if the first remission duration is short (<2 years). Individuals with refractory WM should not be offered [autologous HCT] (level 3, grade B).”
